The classical form of al antitrypsin deficiency (ATD) is one of the most common genetic causes of liver disease. Liver transplantation represents the only treatment currently available for severe liver disease due to ATD. The liver disease associated with ATD is characterized by a stereotypical chronic fibrosis leading to cirrhosis and hepatocyte hyper-proliferation that predisposes to hepatocellular carcinoma. This pathology is attributed to the proteotoxic effect of mutant AT Z that accumulates in the endoplasmic reticulum (ER) of liver cells, a gain-of-toxic function mechanism specific for the polymerogenic tendencies of mutant ATZ. My lab has elucidated the potential mechanisms by which liver cells cope with the proteotoxic effects of ATZ accumulation in the ER including a distinct set of intracellular degradation pathways (proteasomal and autophagic) and a distinct set of signaling pathways that are specifically activated (autophagy, NFKB, ER- and mitochondrial-caspases but not the unfolded protein response). Our working hypothesis is that pharmacological strategies which capitalize on these naturally occurring, presumably protective proteostasis regulatory mechanisms will have a therapeutic effect on the liver disease caused by ATD. Recently, we validated this hypothesis by showing that an autophagy enhancer drug , carbamazepine (CBZ), promotes degradation of ATZ, reduces the hepatic ATZ load and hepatic fibrosis in vivo in a mouse model of ATD. In the work proposed in this application we will pursue this hypothesis further by investigating other drug candidates with putative actions specifically on the autophagy or on the proteasomal system as well as drug candidates such as histone deacetylase inhibitors which may affect the proteostasis network by broad actions on the cellular transcriptome The project will also capitalize on a C. elegans ATD model-based high content screening platform together with computational pharmacological analyses to discover additional therapeutic candidates. Finally, we will investigate the role of other cellular response pathways, such as NFKB signaling, caspase 12, SIDT2 and PIS kinase, in the pathologic effects of ATD to determine whether these pathways could be exploited for novel therapeutic strategies in the future.
This project may lead to new therapeutic strategies for prevention/treatment of liver disease due to a1-antitrypsin deficiency, one of the most frequent genetic diseases for which people undergo liver transplantation.
|O'Reilly, Linda P; Long, Olivia S; Cobanoglu, Murat C et al. (2014) A genome-wide RNAi screen identifies potential drug targets in a C. elegans model of ?1-antitrypsin deficiency. Hum Mol Genet 23:5123-32|
|Long, Olivia S; Benson, Joshua A; Kwak, Joon Hyeok et al. (2014) A C. elegans model of human ?1-antitrypsin deficiency links components of the RNAi pathway to misfolded protein turnover. Hum Mol Genet 23:5109-22|
|Miedel, Mark T; Zeng, Xuemei; Yates, Nathan A et al. (2014) Isolation of serpin-interacting proteins in C. elegans using protein affinity purification. Methods 68:536-41|
|Bhatia, Sangeeta N; Underhill, Gregory H; Zaret, Kenneth S et al. (2014) Cell and tissue engineering for liver disease. Sci Transl Med 6:245sr2|
|O'Reilly, Linda P; Luke, Cliff J; Perlmutter, David H et al. (2014) C. elegans in high-throughput drug discovery. Adv Drug Deliv Rev 69-70:247-53|
|Chu, Andrew S; Perlmutter, David H; Wang, Yan (2014) Capitalizing on the autophagic response for treatment of liver disease caused by alpha-1-antitrypsin deficiency and other genetic diseases. Biomed Res Int 2014:459823|
|O'Reilly, Linda P; Perlmutter, David H; Silverman, Gary A et al. (2014) *1-antitrypsin deficiency and the hepatocytes - an elegans solution to drug discovery. Int J Biochem Cell Biol 47:109-12|
|Li, Jie; Pak, Stephen C; O'Reilly, Linda P et al. (2014) Fluphenazine reduces proteotoxicity in C. elegans and mammalian models of alpha-1-antitrypsin deficiency. PLoS One 9:e87260|
|Fox, Ira J; Daley, George Q; Goldman, Steven A et al. (2014) Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease. Science 345:1247391|
|Wang, Yan; Perlmutter, David H (2014) Targeting intracellular degradation pathways for treatment of liver disease caused by *1-antitrypsin deficiency. Pediatr Res 75:133-9|
Showing the most recent 10 out of 14 publications